Outcome of polypoidal choroidal vasculopathy at 1 year by combined therapy of photodynamic therapy with ranibizumab and predictive factors governing the outcome

Eye (Basingstoke)

Volumn 28, Issue 12, 2014, Pages 1469-1476

  Ho, M ^a   Lo, E C F ^a   Young, A L ^a   Liu, D T L ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

RANIBIZUMAB; VERTEPORFIN; ANGIOGENESIS INHIBITOR; COLORING AGENT; INDOCYANINE GREEN; MONOCLONAL ANTIBODY; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADULT; AGED; ANGIOGRAPHY; ARTICLE; CHOROID VASCULARIZATION; FEMALE; FOLLOW UP; HUMAN; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; MALE; PHOTODYNAMIC THERAPY; POLYPOIDAL CHOROIDAL VASCULOPATHY; PREDICTION; RETINA HEMORRHAGE; TREATMENT OUTCOME; VISION; VISUAL ACUITY; ANTAGONISTS AND INHIBITORS; CHOROIDAL NEOVASCULARIZATION; DRUG COMBINATION; FLUORESCENCE ANGIOGRAPHY; INTRAVITREAL DRUG ADMINISTRATION; MIDDLE AGED; PATHOLOGY; PATHOPHYSIOLOGY; PHOTOCHEMOTHERAPY; PHYSIOLOGY; POLYPS; RETINA FOVEA; RETROSPECTIVE STUDY; VERY ELDERLY;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; CHOROIDAL NEOVASCULARIZATION; COLORING AGENTS; DRUG THERAPY, COMBINATION; FEMALE; FLUORESCEIN ANGIOGRAPHY; FOLLOW-UP STUDIES; FOVEA CENTRALIS; HUMANS; INDOCYANINE GREEN; INTRAVITREAL INJECTIONS; MALE; MIDDLE AGED; PHOTOCHEMOTHERAPY; POLYPS; RANIBIZUMAB; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VISUAL ACUITY;

EID: 84927586942     PISSN: 0950222X     EISSN: 14765454     Source Type: Journal    
DOI: 10.1038/eye.2014.222     Document Type: Article

References (33)

1. Yannuzzi LA, Sorenson J, Spaide RF, Lipson B. Idiopathic polypoidal choroidal vasculopathy (IPCV). 1990. Retina 2012; 32(Suppl 1): 1-8
2. Ciardella AP, Donsoff IM, Huang SJ, Costa DL, Yannuzzi LA. Polypoidal choroidal vasculopathy. Surv Ophthalmol 2004; 49(1): 25-37
3. Chan WM, Lam DS, Lai TY, Liu DT, Li KK, Yao Y et al. Photodynamic therapy with verteporfin for symptomatic polypoidal choroidal vasculopathy: one-year results of a prospective case series. Ophthalmology 2004; 111(8): 1576-1584
4. Gomi F, Ohji M, Sayanagi K, Sawa M, Sakaguchi H, Oshima Y et al. One-year outcomes of photodynamic therapy in age-related macular degeneration and polypoidal choroidal vasculopathy in Japanese patients. Ophthalmology 2008; 115(1): 141-146
5. Silva RM, Figueira J, Cachulo ML, Duarte L, Faria de Abreu JR, Cunha-Vaz JG. Polypoidal choroidal vasculopathy and photodynamic therapy with verteporfin. Graefe's Arch Clin Exp Ophthalmol 2005; 243(10): 973-979
6. Otani A, Sasahara M, Yodoi Y, Aikawa H, Tamura H, Tsujikawa A et al. Indocyanine green angiography: guided photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2007; 144(1): 7-14
7. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K et al. Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Retina 2013; 33: 1949-1958
8. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K et al. One-year results of three monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Am J Ophthalmol 2012; 154(1): 117-24 e1
9. Yuzawa M, Mori R, Kawamura A. The origins of polypoidal choroidal vasculopathy. Br J Ophthalmol 2005; 89(5): 602-607
10. Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ et al. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration. Am J Ophthalmol 2007; 143(4): 566-583
11. Lalwani GA, Rosenfeld PJ, Fung AE, Dubovy SR, Michels S, Feuer W et al. A variable-dosing regimen with intravitreal ranibizumab for neovascular age-related macular degeneration: year 2 of the PrONTO Study. Am J Ophthalmol 2009; 148(1): 43-58 e1
12. Cho HJ, Kim JW, Lee DW, Cho SW, Kim CG. Intravitreal bevacizumab and ranibizumab injections for patients with polypoidal choroidal vasculopathy. Eye (Lond) 2012; 26(3): 426-433
13. Lai TY, Lee GK, Luk FO, Lam DS. Intravitreal ranibizumab with or without photodynamic therapy for the treatment of symptomatic polypoidal choroidal vasculopathy. Retina 2011; 31(8): 1581-1588
14. Gomi F, Sawa M, Sakaguchi H, Tsujikawa M, Oshima Y, Kamei M et al. Efficacy of intravitreal bevacizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2008; 92(1): 70-73
15. Koh A, Lee WK, Chen LJ, Chen SJ, Hashad Y, Kim H et al. EVEREST study: efficacy and safety of verteporfin photodynamic therapy in combination with ranibizumab or alone versus ranibizumab monotherapy in patients with symptomatic macular polypoidal choroidal vasculopathy. Retina 2012; 32(8): 1453-1464
16. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Nishida K. Intravitreal bevacizumab for exudative branching vascular networks in polypoidal choroidal vasculopathy. Br J Ophthalmol 2012; 96(3): 394-399
17. Lai TY, Chan WM, Lam DS. Transient reduction in retinal function revealed by multifocal electroretinogram after photodynamic therapy. Am J Ophthalmol 2004; 137(5): 826-833
18. Maruko I, Iida T, Sugano Y, Saito M, Sekiryu T. Subfoveal retinal and choroidal thickness after verteporfin photodynamic therapy for polypoidal choroidal vasculopathy. Am J Ophthalmol 2011; 151(4): 594-603 e1
19. Ho M, Liu DT, Chan VC, Lam DS. Choroidal thickness measurement in myopic eyes by enhanced depth optical coherence tomography. Ophthalmology 2013; 120(9): 1909-1914
20. Oishi A, Kojima H, Mandai M, Honda S, Matsuoka T, Oh H et al. Comparison of the effect of ranibizumab and verteporfin for polypoidal choroidal vasculopathy: 12-month laptop study results. Am J Ophthalmol 2013; 156: 644-651
21. Wakabayashi T, Gomi F, Sawa M, Tsujikawa M, Tano Y. Marked vascular changes of polypoidal choroidal vasculopathy after photodynamic therapy. Br J Ophthalmol 2008; 92(7): 936-940
22. Saito M, Iida T, Kano M. Combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Retina 2012; 32(7): 1272-1279
23. Saito M, Iida T, Kano M, Itagaki K. Two-year results of combined intravitreal ranibizumab and photodynamic therapy for polypoidal choroidal vasculopathy. Graefes Arch Clin Exp Ophthalmol 2013; 251(9): 2099-2110
24. Sato T, Kishi S, Matsumoto H, Mukai R. Combined photodynamic therapy with verteporfin and intravitreal bevacizumab for polypoidal choroidal vasculopathy. Am J Ophthalmol 2010; 149(6): 947-54 e1
25. Tomita K, Tsujikawa A, Yamashiro K, Ooto S, Tamura H, Otani A et al. Treatment of polypoidal choroidal vasculopathy with photodynamic therapy combined with intravitreal injections of ranibizumab. Am J Ophthalmol 2012; 153(1): 68-80 e1
26. Hikichi T, Ohtsuka H, Higuchi M, Matsushita T, Ariga H, Kosaka S et al. Factors predictive of visual acuity outcomes 1 year after photodynamic therapy in Japanese patients with polypoidal choroidal vasculopathy. Retina 2011; 31(5): 857-865
27. Koizumi H, Yamagishi T, Yamazaki T, Kinoshita S. Predictive factors of resolved retinal fluid after intravitreal ranibizumab for polypoidal choroidal vasculopathy. Br J Ophthalmol 2011; 95(11): 1555-1559
28. Saito M, Iida T, Nagayama D. Photodynamic therapy with verteporfin for age-related macular degeneration or polypoidal choroidal vasculopathy: comparison of the presence of serous retinal pigment epithelial detachment. Br J Ophthalmol 2008; 92(12): 1642-1647
29. Tsujikawa A, Ojima Y, Yamashiro K, Nakata I, Ooto S, Tamura H et al. Association of lesion size and visual prognosis to polypoidal choroidal vasculopathy. Am J Ophthalmol 2011; 151(6): 961-72 e1
30. Yamashiro K, Tomita K, Tsujikawa A, Nakata I, Akagi-Kurashige Y,MiyakeMet al. Factors associated with the response of age-related macular degeneration to intravitreal ranibizumab treatment. Am J Ophthalmol 2012; 154(1): 125-136
31. Kang HM, Koh HJ, Lee CS, Lee SC. Combined photodynamic therapy with intravitreal bevacizumab injections for polypoidal choroidal vasculopathy: long-term visual outcome. Am J Ophthalmol 2014; 157(3): 598-606 e1
32. Hikichi T, Higuchi M, Matsushita T, Kosaka S, Matsushita R, Takami K et al. Factors predictive of outcomes 1 year after 3 monthly ranibizumab injections and as-needed reinjections for polypoidal choroidal vasculopathy in Japanese patients. Retina 2013; 33(9): 1949-1958
33. Mori R, Yuzawa M, Lee Z, Haruyama M, Akaza E. Factors influencing visual outcome of polypoidal choroidal vasculopathy 1 year after photodynamic therapy. Graefes Arch Clin Exp Ophthalmol 2010; 248(9): 1233-1239.